Back to Journals » Infection and Drug Resistance » Volume 3

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Authors Chirch L, Steigbigel RT

Published 26 April 2010 Volume 2010:3 Pages 15—23

DOI https://doi.org/10.2147/IDR.S9689

Review by Single-blind

Peer reviewer comments 2


Lisa M Chirch, Roy T Steigbigel

Division of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA

Abstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.
Keywords: raltegravir, integrase, human immunodeficiency virus, drug resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]